
PG&E's Diablo Canyon vessel report meets NRC surveillance rules
NRC staff found a Unit 1 reactor-vessel report met federal requirements on Sept. 24, months after renewing the plant's operating licences.

The Quebrada Dorada discovery extends the known gold mineralized trend at Fruta del Norte beyond eight kilometres.

NRC staff found a Unit 1 reactor-vessel report met federal requirements on Sept. 24, months after renewing the plant's operating licences.

The seven-year CPU services agreement carries delivery conditions, a preferred-share warrant and a projected late 2027 service start.
The small ALTITUDE follow-up lacks a control comparison; the dose is being tested in the sham-controlled NAAVIGATE trial.
Holders will weigh a new parent company, a Delaware move and a voting-share sunset extension as Cresco pursues a potential U.S. listing.

The applications pair LSD, ketamine and ibogaine with N-acylethanolamines, while the scope of any patent rights remains undecided.

A Sept. 24 federal notice opens intervention in Transco's Pennsylvania pipeline application, while Williams targets late 2027 service.

A CAD administration role accounts for US$57,127 of the forecast; a US$3.43M ten-year value depends on continued authorization.

It counted 180 new customer contracts through Sept. 23 but gave no schedule for recognizing their value as revenue.
Curaleaf urged a signature on Sept. 23; A10698B would let regulators seek suspensions and impose daily civil penalties.
The company gave no sale proceeds or new cash balance, leaving its June 30 cash of US$21.0 million as the latest figure disclosed in the releases.
Elegancia will deliver the Qatari facility in two phases, but the companies gave no power rating or completion date.
Aurora cites missing pro forma financials, a French-language notice and the mandatory 105-day deposit period in its ASC application.
June-quarter sales fell to about US$13,500, while a post-year-end secured loan added US$20 million in initial funding.
The acquired portfolio spans 862 square kilometres in central Saudi Arabia, with historic gold intercepts at Jabal Jumaymah and Wadi Jarir.
Three of six initial holes have assays as drilling tests the newly leased ground between two mineralized areas at Slumber.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
Selected historic core from Colombia also held magnet rare earth oxides, but continuity and recovery remain untested.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
Both doses passed a vision noninferiority test against ranibizumab; higher rates of retinal complications await detail.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The three-year Saudi program can run two years longer, but SLB did not disclose a contract value or a first-well date.
Adjusted EPS beat BlackBerry's June outlook, while the company forecast a sharp licensing revenue decline in the next quarter.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
PEJ aims to finish negotiations by year-end 2026 for three AP1000 units totaling 3,750 MWe; the EPC price remains undisclosed.

The Sept. 21 term sheet mixes direct investment and engineering services, requires approvals and leaves Samsung's cash share and equity stake undisclosed.

The signed development-zone agreement adds a counterparty, while financing still governs the new lines and a separate expansion targets year-end.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
Advisers voted 10 to 0 on safety and 6 to 4 on effectiveness; the FDA has not set a date for its final decision.

A 51 per cent stake in a Polish drone company remains a non-binding proposal, while the registered share sale is expected to close Sept. 24.

The Health Canada-authorized depression study plans to enroll up to 200 people, while the batch also serves Australian clinics.

The addition gives Curaleaf a second Canadian benchmark, but its Sept. 23 release does not quantify any resulting fund purchases.